MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
Alnylam Pharmaceuticals EBITDA per Share 2011-2026 | ALNY
Annual EBITDA per Share Alnylam Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.25 | -0.94 | -1.83 | -6.09 | -5.58 | -6.9 | -8.1 | -8.03 | -5.37 | -4.78 | -3.3 | -2.32 | -1.34 | -1.08 | -1.17 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.25 | -8.1 | -3.51 |
Quarterly EBITDA per Share Alnylam Pharmaceuticals
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 0.25 | - | - | - | -0.24 | - | - | - | -1.09 | - | -1.87 | -1.59 | -1.14 | - | -1.22 | -1.24 | -1.48 | - | -1.73 | -1.59 | -1.8 | - | -1.88 | -2.11 | -1.75 | - | -2.47 | -1.86 | -1.44 | - | -1.26 | -1.3 | -1.2 | - | -1.1 | -0.98 | -1.24 | - | -0.76 | -0.76 | -0.59 | - | -0.48 | -0.52 | -3.93 | - | -0.39 | -0.27 | -0.13 | - | -0.22 | -0.14 | -0.19 | - | -0.2 | -0.25 | -0.34 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 0.25 | -3.93 | -1.09 |
EBITDA per Share of other stocks in the Biotechnology industry
| Issuer | EBITDA per Share | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ADC Therapeutics SA
ADCT
|
-3.41 | $ 3.78 | - | $ 105 M |  Schweiz |
 |
MorphoSys AG
MOR
|
-15.2 | - | 2.43 % | $ 254 M |  Germany |
 |
Akebia Therapeutics
AKBA
|
0.1 | $ 1.35 | -2.17 % | $ 347 M |  USA |
 |
Akari Therapeutics, Plc
AKTX
|
-0.67 | $ 3.5 | -21.7 % | $ 236 B |  Britain |
 |
Aldeyra Therapeutics
ALDX
|
-0.58 | $ 1.58 | -4.82 % | $ 94.9 M | USA |
 |
Aligos Therapeutics
ALGS
|
-8.81 | $ 8.36 | 4.89 % | $ 82.6 M | USA |
 |
Altimmune
ALT
|
-1.07 | $ 3.47 | 3.89 % | $ 306 M | USA |
 |
ALX Oncology Holdings
ALXO
|
-1.93 | $ 1.98 | 0.25 % | $ 106 M | USA |
 |
Amgen
AMGN
|
26.5 | $ 346.45 | -0.43 % | $ 186 B | USA |
 |
I-Mab
IMAB
|
0.08 | - | - | $ 866 M |  China |
 |
Amneal Pharmaceuticals
AMRX
|
1.44 | $ 12.37 | -0.92 % | $ 3.88 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.75 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-2.24 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-0.23 | - | -13.47 % | $ 169 M | France |
 |
Anika Therapeutics
ANIK
|
-5.54 | $ 15.0 | 1.32 % | $ 220 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
3.54 | $ 76.34 | 2.87 % | $ 1.47 B | USA |
 |
Annexon
ANNX
|
-1.38 | $ 5.64 | 2.45 % | $ 875 M | USA |
 |
Aptorum Group Limited
APM
|
0.34 | $ 0.92 | -1.11 % | $ 5.02 M | China |
 |
Midatech Pharma plc
MTP
|
-0.09 | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.22 | - | -1.52 % | $ 24.7 M | USA |
 |
Aprea Therapeutics
APRE
|
-2.02 | $ 0.73 | 2.63 % | $ 4.77 M | USA |
 |
Aquestive Therapeutics
AQST
|
-0.66 | $ 4.15 | 0.48 % | $ 444 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-2.67 | $ 8.43 | 4.98 % | $ 231 M |  Israel |
 |
Ardelyx
ARDX
|
-0.16 | $ 6.08 | 2.27 % | $ 1.47 B | USA |
 |
argenx SE
ARGX
|
-6.83 | $ 752.05 | 0.75 % | $ 25 B |  Niderland |
 |
Acorda Therapeutics
ACOR
|
-188 | - | -24.86 % | $ 820 K | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-0.09 | $ 23.93 | 1.27 % | $ 3.04 B | USA |
 |
Arvinas
ARVN
|
-1.63 | $ 11.11 | 2.4 % | $ 788 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-6.85 | - | - | $ 86.2 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
0.9 | $ 61.57 | 0.88 % | $ 8.24 B | USA |
 |
Advaxis
ADXS
|
-5.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Applied Molecular Transport
AMTI
|
-3.2 | - | - | $ 10.1 M | USA |
 |
Assembly Biosciences
ASMB
|
-1.07 | $ 30.01 | 3.43 % | $ 336 M | USA |
 |
Aeterna Zentaris
AEZS
|
-0.08 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-2.35 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
-3.89 | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-6.7 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-4.25 | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-2.45 | - | 0.23 % | $ 488 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
-2.69 | - | - | - |  Russia |
 |
Actinium Pharmaceuticals
ATNM
|
-1.16 | $ 1.14 | 16.28 % | $ 35.6 M | USA |
 |
Atossa Therapeutics
ATOS
|
-4.31 | $ 5.21 | -2.89 % | $ 44.9 M | USA |
 |
Atara Biotherapeutics
ATRA
|
3.03 | $ 5.03 | 0.7 % | $ 63.1 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-0.696 | - | 3.16 % | $ 1.9 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
0.39 | $ 16.04 | 2.75 % | $ 2.16 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
-0.99 | $ 1.42 | 0.35 % | $ 378 M | Britain |
 |
Alpine Immune Sciences
ALPN
|
-1.72 | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-1.99 | - | 10.36 % | $ 9.8 M | USA |